These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31248654)

  • 21. Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania.
    Kutkiene S; Petrulioniene Z; Laucevicius A; Cerkauskiene R; Staigyte J; Saulyte A; Petrulionyte E; Gargalskaite U; Skiauteryte E; Matuzeviciene G; Kovaite M; Rinkuniene E
    Atherosclerosis; 2018 Oct; 277():267-272. PubMed ID: 30270057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf.
    Al-Hashmi K; Al-Zakwani I; Al Mahmeed W; Arafah M; Al-Hinai AT; Shehab A; Al Tamimi O; Al Awadhi M; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FO; Amin H; Santos RD; Al-Waili K; Al-Rasadi K
    J Clin Lipidol; 2016; 10(2):368-77. PubMed ID: 27055968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others.
    Sirtori CR; Fumagalli R
    Atherosclerosis; 2006 May; 186(1):1-11. PubMed ID: 16310198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service.
    Lamprecht DG; Shaw PB; King JB; Hogan KN; Olson KL
    J Clin Lipidol; 2018; 12(4):999-1007. PubMed ID: 29803357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9.
    Quispe R; Al-Hijji M; Swiger KJ; Martin SS; Elshazly MB; Blaha MJ; Joshi PH; Blumenthal RS; Sniderman AD; Toth PP; Jones SR
    J Clin Lipidol; 2015; 9(4):511-8.e1-5. PubMed ID: 26228668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
    J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010.
    Kit BK; Carroll MD; Lacher DA; Sorlie PD; DeJesus JM; Ogden C
    JAMA; 2012 Aug; 308(6):591-600. PubMed ID: 22871871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.
    Mortensen MB; Nordestgaard BG
    Eur Heart J; 2020 Aug; 41(31):3005-3015. PubMed ID: 32227172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events.
    Wu F; Juonala M; Jacobs DR; Daniels SR; Kähönen M; Woo JG; Sinaiko AR; Viikari JSA; Bazzano LA; Burns TL; Steinberger J; Urbina EM; Venn AJ; Raitakari OT; Dwyer T; Magnussen CG
    Circulation; 2024 Jan; 149(3):217-226. PubMed ID: 38014550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High blood cholesterol.
    National Heart, Lung and Blood Institute
    Nutr Clin Care; 2003; 6(3):108-14. PubMed ID: 14979453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.